Key result
Amentoflavone suppresses TAC-induced cardiac hypertrophy and fibrosis in mice by inhibiting TGF-β and MAPK pathways.
Why the study?
Amentoflavone has beneficial effects against several cardiovascular diseases, but its role and mechanisms in pathological cardiac remodeling remain unclear.
Does Amentoflavone alleviate cardiac remodeling and dysfunction in mice with pressure overload?
Does Amentoflavone alleviate cardiac remodeling and dysfunction in mice with pressure overload?
Amentoflavone protects against pathological cardiac remodeling and fibrosis by directly binding to TGF-β receptor 1 and inhibiting TGF-β/Smad and MAPK signaling pathways in preclinical models.
Answers are grounded in this paper and cite their sources.
Amentoflavone may attenuate murine pressure-overload remodeling; leaves open human translation pending clinical trials.
Chronic cardiac stress induces cardiac hypertrophy and fibrosis, thereby promoting pathological heart remodeling, which is the core pathological process of heart failure. Amentoflavone (AMF) has beneficial therapeutic effects against several cardiovascular diseases; however, its role and underlying mechanisms in pathological cardiac remodeling remain unclear. Here, we investigated the protective role of AMF against pathological cardiac remodeling in transverse aortic constriction (TAC)‐induced overloaded hearts. Mice with pressure overload caused by TAC were treated with AMF, and the effects of AMF on cardiac function, cardiac hypertrophy, and fibrosis were analyzed. RNA‐seq, molecular docking, surface plasmon resonance (SPR), and co‐IP were used to identify the downstream targets of AMF. Angiotensin II (Ang II) and transforming growth factor beta 1 (TGF‐β1) were used to characterize the role of AMF and its downstream targets in cardiac hypertrophy and fibrosis in vitro. Sustained AMF administration significantly suppressed TAC‐induced cardiac remodeling. Compared with those in TAC model mice, the heart/body weight ratio, cardiomyocyte cross‐sectional area, and hypertrophic molecular markers were significantly lower in AMF‐treated TAC model mice. Moreover, TAC‐induced myofibroblast generation and extracellular matrix deposition were effectively reversed following AMF administration. Similar results were obtained after AMF treatment for cardiomyocyte hypertrophy and cardiac fibrosis in vitro. Mechanistically, by directly binding to TGF‐β receptor 1, AMF blocked the regulatory effect of TGF‐β1 and inhibited the TGF‐β/Smad and MAPK signaling pathways. These results suggest that AMF, through binding to TGF‐β receptor 1, may be a promising therapeutic option for pathological cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question. Amentoflavone significantly suppressed TAC-induced cardiac hypertrophy and fibrosis by inhibiting TGF-β receptor 1 and blocking TGF-β/Smad and MAPK pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: